Although advances have been achieved in the treatment of CML patients with resistant mutations in the BCR-ABL kinase domain, resistance has not yet been completely overcome because additional resistant mutations against this novel Bcr-ABL inhibitor may emerge. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.